NMD4C Welcomed Investigators to Annual Meeting in Calgary

Thank you to our investigators who attended the 2024 Annual NMD4C Meeting on September 27th in Calgary!

Our meeting program consisted of presentations from pillar and task leads which highlighted their groups’ achievements and progress made to date. The project updates were inspiring to hear, and we are excited to see how our collective efforts will continue to advance our network goals over the coming year. The contributions from the attendees to the discussions and planning have set a strong foundation for the next steps for the year ahead, and we look forward to continuing this momentum. A full meeting summary will be made available to network investigators in the coming weeks.

Additional highlights from our meeting included:

Finally, we would like to thank the organizing team of the WCNMC, which took place directly after our annual meeting. The WCNMC conference provided an excellent forum for the neuromuscular community to gather and learn about clinical practice and research updates, and network with colleagues and we are looking forward to attending again in 2026!

2024 NMD4C Annual Meeting

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.